Concomitant NSAID use during antipsychotic treatment and risk of 2-year relapse – a population-based study of 16,253 incident patients with schizophrenia

References

• Meyer U, Schwarz MJ, Muller N. Inflammatory processes in schizophrenia: a promising neuroimmunological target for the treatment of negative/cognitive symptoms and beyond. Pharmacol Ther. 2011;132:96–110.
   PubMed Web of Science ®Google Scholar
• Benros ME, Nielsen PR, Nordentoft M, et al. Autoimmune diseases and severe infections as risk factors for schizophrenia: a 30-year population-based register study. Am J Psychiatry. 2011;168:1303–1310.
   PubMed Web of Science ®Google Scholar
• Muller N, Myint AM, Schwarz MJ. Inflammation in schizophrenia. Adv Protein Chem Struct Biol. 2012;88:49–68.
   PubMed Web of Science ®Google Scholar
• Nielsen PR, Benros ME, Mortensen PB. Hospital contacts with infection and risk of schizophrenia: a population-based cohort study with linkage of danish national registers. Schizophr Bull. 2014;40:1526–1532.
   PubMed Web of Science ®Google Scholar
• Leza JC, Garcia-Bueno B, Bioque M, et al. Inflammation in schizophrenia: a question of balance. Neurosci Biobehav Rev. 2015;55:612–626.
   PubMed Web of Science ®Google Scholar
• Muller N, Riedel M, Scheppach C, et al. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry. 2002;159:1029–1034.
   PubMed Web of Science ®Google Scholar
• Muller N, Krause D, Dehning S, et al. Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophr Res. 2010;121:118–124.
   PubMed Web of Science ®Google Scholar
• Laan W, Grobbee DE, Selten JP, et al. Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2010;71:520–527.
   PubMed Web of Science ®Google Scholar
• Weiser M, Burshtein S, Fodoreanu L. A randomized trial administering aspirin, minocycline or pramipexole vs placebo as add-on to antipsychotics in patients with schizophrenia or schiz- oaffecive disorder. Neuropsychopharmacology 2012;38:S351.
   Google Scholar
• Stolk P, Souverein PC, Leufkens HG, et al. The association between exposure to COX-2 inhibitors and schizophrenia deterioration. A nested case-control study. Pharmacopsychiatry. 2007;40:111–115.
   PubMed Web of Science ®Google Scholar
• Sommer IE, de Witte L, Begemann M, et al. Nonsteroidal anti-inflammatory drugs in schizophrenia: ready for practice or a good start? A meta-analysis. J Clin Psychiatry. 2012;73:414–419.
   PubMed Web of Science ®Google Scholar
• Nitta M, Kishimoto T, Muller N, et al. Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials. Schizophr Bull. 2013;39:1230–1241.
   PubMed Web of Science ®Google Scholar
• Sommer IE, van Westrhenen R, Begemann MJ, et al. Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update. Schizophr Bull. 2014;40:181–191.
   PubMed Web of Science ®Google Scholar
• Hinz B, Cheremina O, Brune K. Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man. Faseb J. 2008;22:383–390.
   PubMed Web of Science ®Google Scholar
• Kildemoes HW, Sorensen HT, Hallas J. The danish national prescription registry. Scand J Public Health. 2011;39:38–41.
   PubMed Web of Science ®Google Scholar
• Mors O, Perto GP, Mortensen PB. The danish psychiatric central research register. Scand J Public Health. 2011;39:54–57.
   PubMed Web of Science ®Google Scholar
• Uggerby P, Ostergaard SD, Roge R, et al. The validity of the schizophrenia diagnosis in the danish psychiatric central research register is good. Dan Med J. 2013;60:A4578.
   PubMed Web of Science ®Google Scholar
• Pedersen CB. The danish civil registration system. Scand J Public Health. 2011;39:22–25.
   PubMed Web of Science ®Google Scholar
• Schmidt M, Hallas J, Friis S. Potential of prescription registries to capture individual-level use of aspirin and other nonsteroidal anti-inflammatory drugs in denmark: trends in utilization 1999–2012. Clin Epidemiol May. 2014;2014(6):155–168.
   Google Scholar
• Sorensen HJ, Larsen JT, Mors O, et al. Analysis of risk factors for schizophrenia with two different case definitions: a nationwide register-based external validation study. Schizophr Res. 2015;162:74–78.
   PubMed Web of Science ®Google Scholar
• Köhler O, Petersen L, Mors O, et al.. Inflammation and depression: combined use of selective serotonin-reuptake inihibitors and NSAIDs or paracetamol and psychiatric outcomes. Brain Behav. 2015 Aug;5(8):e00338.
   PubMed Web of Science ®Google Scholar
• Knights KM, Mangoni AA, Miners JO. Defining the COX inhibitor selectivity of NSAIDs: implications for understanding toxicity. Expert Rev Clin Pharmacol. 2010;3:769–776.
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Haukka J, Taylor M, et al. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry. 2011;168:603–609.
   PubMed Web of Science ®Google Scholar
• Olivares JM, Sermon J, Hemels M, et al. Definitions and drivers of relapse in patients with schizophrenia: a systematic literature review. Ann Gen Psychiatry. 2013;12:32859X1232.
   Google Scholar
• Jensen VM, Rasmussen AW. Danish education registers. Scand J Public Health. 2011;39:91–94.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–383.
   PubMedGoogle Scholar
• Almeida OP, Alfonso H, Jamrozik K, et al. Aspirin use, depression, and cognitive impairment in later life: the health in men study. J Am Geriatr Soc. 2010;58:990–992.
   PubMed Web of Science ®Google Scholar
• Lynge E, Sandegaard JL, Rebolj M. The danish national patient register. Scand J Public Health. 2011;39:30–33.
   PubMed Web of Science ®Google Scholar
• de Abajo FJ, Garcia-Rodriguez LA. Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: interaction with nonsteroidal anti-inflammatory drugs and effect of acid-suppressing agents. Arch Gen Psychiatry. 2008;65:795–803.
   PubMed Web of Science ®Google Scholar
• Schjerning Olsen AM, Fosbol EL, Lindhardsen J, et al. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation. 2011;123:2226–2235.
   PubMed Web of Science ®Google Scholar
• Phelan M, Stradins L, Morrison S. Physical health of people with severe mental illness. BMJ. 2001;322:443–444.
   PubMed Web of Science ®Google Scholar
• Song X, Fan X, Song X, et al. Elevated levels of adiponectin and other cytokines in drug naive, first episode schizophrenia patients with normal weight. Schizophr Res. 2013;150:269–273.
   PubMed Web of Science ®Google Scholar
• Kohler O, Benros ME, Nordentoft M, et al. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry. 2014;71:1381–1391.
   PubMed Web of Science ®Google Scholar
• Fond G, d’Albis MA, Jamain S, et al. The promise of biological markers for treatment response in first-episode psychosis: a systematic review. Schizophr Bull. 2015;41:559–573.
   PubMed Web of Science ®Google Scholar
• Gleeson JF, Alvarez-Jimenez M, Cotton SM, et al. A systematic review of relapse measurement in randomized controlled trials of relapse prevention in first-episode psychosis. Schizophr Res. 2010;119:79–88.
   PubMed Web of Science ®Google Scholar